You can contact your insurance plan directly for coverage and cost information
Kittanamongkolchai W, Mara KC, Mehta RA, Vaughan LE, Denic A, Knoedler JJ, et al
Large clinical trials, including SUSTAIN-6 and PIONEER-6, demonstrated that semaglutide significantly reduced major adverse cardiovascular events compared to placebo, with risk reductions of approximately 24 percent in high-risk populations (20)
While the RNI for maintenance is only 1.5 g daily, therapeutic oral doses typically range from: 50-150 g daily for mild deficiency prevention in at-risk groups 1,000-2,000 g daily for treating confirmed deficiency without malabsorption Some formulations contain up to 5,000 g, though there is no proven additional benefit over 1,000-2,000 g for most patients The reason for this dosage discrepancy lies in absorption efficiency